BUSINESS● LOWSep 3 · Sep 3, 2026, 3:31 PM
Ultragenyx slides amid multiple downgrades on trial setback for Angelman syndrome drug
Seeking Alpha Tech · north america
Ultragenyx shares have declined after multiple downgrades stemming from a trial setback for its Angelman syndrome drug. This highlights a negative development for the company's pharmaceutical pipeline.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Business
BUSINESSnowMunicipal Securities Underwriters Pay a Total of $325,000 in FinesSECBUSINESSnowSEC CHAIRMAN ARTHUR LEVITT, IOWA OFFICIALS TO HOLD INVESTORS’ TOWN MEETING IN DES MOINESSECBUSINESS5m agoZedge Q4 2026 Earnings PreviewSeeking Alpha TechBUSINESS5m agoH2O Q3 2026 Earnings PreviewSeeking Alpha Tech